NASDAQ · BLSM
BlossomHill Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BLSM: Dec 18, 2026
BlossomHill Therapeutics, Inc. Common Stock is estimated to report earnings on 12/18/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.93.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.93 | $-0.92 | $-0.93 | 2 |
| Dec 2026 | $-1.00 | $-0.92 | $-1.08 | 2 |
| Mar 2027 | $-0.86 | $-0.86 | $-0.86 | 1 |
| Jun 2027 | $-0.77 | $-0.77 | $-0.77 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · Oct 2, 6:14 AM EDTBlossomHill Therapeutics Average Analyst Price Target Raised 10.53% to $37.48The average one-year price target for BlossomHill Therapeutics (NASDAQGS:BLSM) has been revised to $37.48 / share. This is an increase of 10.53% from the prior estimate of $33.92 dated September 11, 2026. These figures represent an aggregate of analyst targets compiled by Fintel
- RTTNews · Sep 22, 9:53 AM EDTBiotech Stocks At 52-Week Highs – AMRX, BLSM, NEOG. NEO(RTTNews) – The following biotech stocks reached a 52-week high on September 22, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.
- RTTNews · Sep 18, 8:45 AM EDTBlossomHill Q2 Loss Widens; BH-30643 Advances, Balance Sheet Strengthens(RTTNews) – BlossomHill Therapeutics, Inc. (BLSM) reported second-quarter 2026 financial results and a business update, highlighting regulatory progress for BH-30643, advancement of its oncology pipeline and a strengthened balance sheet following its $168.3 million initial public
- RTTNews · Sep 17, 4:10 AM EDTBiotech Stocks At 52-Week Highs – BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG(RTTNews) – The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.
- RTTNews · Sep 15, 8:52 AM EDTBlossomHill's BH-30643 Shows 45% Response In EGFR C797S NSCLC; Stock Up(RTTNews) – BlossomHill Therapeutics Inc. (BLSM) presented updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643.
- RTTNews · Sep 15, 6:06 AM EDTBlossomHill To Present Updated SOLARA Data On BH-30643 In EGFR-Mutant Lung Cancer Today; Stock Up(RTTNews) – BlossomHill Therapeutics, Inc. (BLSM) will present updated data today from its ongoing Phase 1/2 SOLARA trial evaluating BH-30643, the company's investigational macrocyclic OMNI-EGFR inhibitor, in patients with EGFR-mutant NSCLC, who have developed secondary resistanc
- RTTNews · Sep 9, 3:06 AM EDTBiotech Stocks At 52-Week Highs – PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH(RTTNews) – The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 recep
- RTTNews · Aug 31, 5:01 AM EDTBiotech Stocks At 52-Week Highs – RNXT +12%, BLSM, RVTY, ATRC, BFRI(RTTNews) – The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.
- RTTNews · Aug 28, 5:57 AM EDTBiotech Stocks At 52-Week Highs – NEO, BLSM, RVMD, ORMP, CADL(RTTNews) – The following biotech stocks reached a 52-week high on August 27, 2026, driven by key catalysts like various regulatory milestones.
- RTTNews · Aug 18, 8:23 AM EDTBlossomHill Wins FDA Fast Track For BH-30643 In EGFR-Mutant NSCLC;Stock Up(RTTNews) – BlossomHill Therapeutics, Inc. (BLSM) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adults with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-sma
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for BlossomHill Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.